Regenxbio
RGNX
166 hedge funds and large institutions have $399M invested in Regenxbio in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 63 increasing their positions, 51 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
24% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 51
16% more capital invested
Capital invested by funds: $345M → $399M (+$54.3M)
4% more funds holding
Funds holding: 159 → 166 (+7)
7% less call options, than puts
Call options by funds: $1.52M | Put options by funds: $1.64M
1.49% less ownership
Funds ownership: 83.37% → 81.88% (-1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.27M |
| 2 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$3.78M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
+$3.54M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.18M |
| 5 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.54M |
| 2 |
Renaissance Technologies
New York
|
-$3.76M |
| 3 |
BlackRock
New York
|
-$3.43M |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$2.55M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.09M |
RGNX Hedge Fund Activity: Q3 2025 in Review
166 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2025, worth a combined $399M — up 16% from $345M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new RGNX positions and 15 closed out — a net gain of 8 holders — while 63 added to existing stakes and 51 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $6.27M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $6.54M sold.
- 166 institutional investors held Regenxbio (RGNX) as of Q3 2025, up from 159 in Q2 2025.
- Funds reported $399M of Regenxbio stock for Q3 2025, up 16% quarter-over-quarter.
- 23 funds opened new Regenxbio positions in Q3 2025 and 15 closed out, a net change of +8 holders.
- The largest Regenxbio buyer in Q3 2025 was Morgan Stanley, an estimated $6.27M added.
- The largest Regenxbio seller in Q3 2025 was Balyasny Asset Management, an estimated $6.54M sold.
Based on aggregated 13F filings for Q3 2025.